1,721,523 research outputs found
Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC)
No full textNeutropenia and subsequent infections are common events that limit treatment of non-small cell lung cancer (NSCLC). Granulocyte growth factors (G- and GM-CSF) have been introduced in clinical practice and their use has yielded a reduction of the infection risk related to chemotherapy and a dose increase of drug delivery. Randomized clinical trials have shown that granulocyte colony-stimulating factors and, more recently, the longer-acting pegylated granulocyte colony-stimulating factor (pegfilgrastim) effectively reduce the incidence and severity of neutropenia and of its complications. Recommendations for the use of haematopoietic colony-stimulating factors from the American Society of Clinical Oncology (ASCO) have been published in 1994 and updated in 1996, 1997 and 2000. Recently, moreover, National Comprehensive Cancer Network (NCCN) guidelines for the myeloid growth factors in cancer treatment make available. Chemotherapy-associated myelosuppression is a major limitation of anticancer therapy also in early stage, local advanced and metastatic NSCLC. Recently, dose-dense chemotherapy has been shown to improve the outcome in early stage breast cancer and non-Hodgkin's lymphoma. However, few randomized trials have been reported on chemotherapy with or without granulocyte growth factors as primary prophylaxis in NSCLC. Presently, there is no evidence for a benefit in response rate and survival from the use of granulocyte growth factors as support of chemotherapy, in particular, for locally advanced and metastatic NSCLC. In clinical practice, the role of granulocyte growth factors for NSCLC treatment should be limited following the guidelines. An appropriate use of granulocyte growth factors may reduce the overall cost of treatment and improve the quality of life, important aims in the treatment of patients with local advanced or metastatic NSCLC. In the future, we need to identify patients who can benefit from granulocyte growth factors for optimize the schedule and doses, in advanced disease and also, after the recent positive results of adjuvant chemotherapy, in early stages. This review summarizes the present knowledge on the use of granulocyte growth factors in NSCLC. © 2005 Elsevier Ireland Ltd. All rights reserved
L'autonomia privata in sede di separazione consensuale, di divorzio congiunto e di negoziazione assistita
No full textIl saggio descrive l'evoluzione dell'autonomia privata nella crisi familiare. Si affrontano diversi aspetti relativi a tale evoluzione anche alla luce delle novità legislative. In particolare si analizzano le problematiche relative agli accordi a latere della separazione e del divorzio, quelli relativi agli accordi sull'assegno di mantenimento. Il lavoro esamina altresì la questione relativa ai patti in vista del divorzio e la tematica dei trasferimenti immobiliari nei procedimenti di separazione consensuale, divorzio congiunto ed in sede di negoziazione assistita
Brevi note in tema di prescrizione dell'azione di regresso per il mantenimento del figlio a margine di una recente sentenza del Tribunale di Roma
No full textThe principle that the parents are jointly liable for their children’s support can be considered
well established in legal writings and case law; with the resulting right for the parent who
provides entirely for the child support to raise a claim to recover the quota that the other failed
to pay. More discussed, however, is the dies a quo of the limitation period for the exercise of
this right. The Supreme Court considers that the parents’ obligation to support children arises
at their birth, but that proceedings against the parent that fails to pay his quota of the support
can only be instituted after the final judgment declaring the natural paternity. The limitation
period should start therefore only from that moment. Some scholars, and even a judgment of
the Court of Rome of 2014, consider, instead, that the right to bring an action is not subject to
a final judgment on the natural paternity and that the term of the limitation period begins to
run from every single expenditure effected. With this last pronunciation, the Court of Rome
departs from its previous decision of 2014, joining the position of the Supreme Court
PCN96 Oral Vinorelbine Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-Line Treatment for Patients with Advanced non- Squamous non- Small Cell Lung Cancer: a Cost Minimization Analysis in Twelve European Countries
No full text
- …
